科兴制药与智享生物达成生物药开发合作
近日，智享生物与科兴生物制药股份有限公司（简称：科兴制药，股票代码：688136.SH）正式签署战略合作协议，双方将合作开发大分子药物。 （签约代表合影） 签约仪式上，智享生物董事长李智对合作充满期待,他表示：“此次合作不仅是项目的推进，更是双方优势能力的战略互补与整合。智享生物将充分发挥在大分子药物全流程开发与商业化生产方面的核心优势，致力于加速项目的高质量落地，与科兴制药携手开拓国际市场，共同为全球患者提供更高品质的生物药选择。” 科兴制药总经理赵彦轻也强调：“中国生物药产业链已日渐完善，资源整合有助于进一步提高科兴制药的研发效率，丰富产品线，高效推动公司全球业务的发展壮大。” 未来，科兴制药将紧抓市场机遇，加快国际化步伐，向创新型跨国生物制药企业迈进。智享生物也期待依托超过10万升的已投产产能，以及高效、灵活、可扩展的生产体系，为项目的高品质、高效率与高稳定性供应提供坚实保障，也进一步夯实我们作为行业可信赖合作伙伴的承诺。 关于科兴制药 About Kexing Biopharm 科兴制药（股票代码：688136）是一家专注于重组蛋白、多功能抗体、细胞基因治疗等药物的研发、生产、销售一体化的创新型跨国生物制药企业。聚焦抗肿瘤、自身免疫、抗病毒等治疗领域，围绕未被满足的临床需求，打造新型蛋白、新型抗体、核酸药物等前沿生物技术平台，开发精准治疗及新型靶向递送药物，坚持“创新+国际化”双轮驱动的平台型发展模式，致力于成为高品质生物药领导者，服务全球患者。 Intellective Bio (Suzhou) Co., Ltd. has entered into a strategic cooperation agreement with Kexing Biopharm Co., Ltd. (Stock Code: 688136.SH). This partnership is centered on the joint development of large molecule therapeutics. At the signing ceremony, Alex Li, Chairman of Intellective Bio, shared his enthusiasm for the collaboration, stating, 'This initiative represents not only a significant step forward in project execution but also a strategic alignment and integration of our respective strengths. Intellective Bio will leverage its core expertise in end-to-end development and commercial-scale manufacturing of biologics to ensure the high-quality and timely advancement of these programs. We are proud to join forces with Kexing Biopharm to expand into international markets and deliver enhanced biologic treatment options to patients worldwide.' Mr. Zhao Yanqing, General Manager of Kexing Biopharm, also emphasized, 'With the biopharmaceutical ecosystem in China becoming increasingly mature, this collaboration will further enhance Kexing Biopharm’s R&D efficiency and diversify our product pipeline, driving the growth of our global operations.' Looking ahead, Kexing Biopharm is committed to capitalizing on emerging market opportunities and accelerating its global strategy to evolve into an innovative multinational biopharmaceutical company. Supported by over 100,000 liters of operational production capacity and a highly efficient, flexible, and scalable manufacturing platform, Intellective Bio is well-positioned to ensure robust, reliable, and high-quality supply for the collaboration. This partnership further strengthens our pledge to be a trusted and capable CDMO partner in the global biopharmaceutical industry.
